Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia

Hiroyuki Nakai, S. Misawa, S. Horiike, T. Maekawa, K. Kashima, K. Ishizaki

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We analysed the expression of the p53 gene in various clinical phases of chronic myelogenous leukaemia (CML) by quantitative reverse transcriptase (RT) polymerase chain reaction (PCR). Hemizygous expression of the wild-type p53 allele was observed in two samples showing the loss of one p53 allele, and affected p53 expression was associated with p53 allelic loss rather than the clinical phase of CML. In four patients with CML showing p53 inactivation, we performed a detailed sequential analysis of p53 allelic loss, p53 mutation and expression from the onset of the disease to the patients' death. Consequently, we demonstrated that the loss of a wild-type p53 allele preceded mutation of the remaining allele, and that cells hemizygous for the wild-type p53 allele dominated those with both wild-type alleles, then were replaced by cells with complete p53 inactivation. These observations indicate that not only complete p53 inactivation but also hemizggous expression of the wild-type p53 allele may confer a selective growth advantage, and that the former is implicated in a more malignant phase than the latter. Alternatively, the inactivation of another undefined anti-oncogene on chromosome 17p may allow selective growth before the p53 mutation occurs.

Original languageEnglish (US)
Pages (from-to)147-155
Number of pages9
JournalBritish Journal of Haematology
Volume90
Issue number1
StatePublished - 1995
Externally publishedYes

Fingerprint

p53 Genes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Alleles
Growth
Leukemia, Myeloid, Chronic Phase
Loss of Heterozygosity
Mutation
Tumor Suppressor Genes
Reverse Transcriptase Polymerase Chain Reaction
Chromosomes

Keywords

  • Blast crisis
  • Chromosome aberration
  • Chronic myerogenous leukaemia
  • Messenger RNA
  • p53

ASJC Scopus subject areas

  • Hematology

Cite this

Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia. / Nakai, Hiroyuki; Misawa, S.; Horiike, S.; Maekawa, T.; Kashima, K.; Ishizaki, K.

In: British Journal of Haematology, Vol. 90, No. 1, 1995, p. 147-155.

Research output: Contribution to journalArticle

@article{0a7d45309b844232893e89f15b29c991,
title = "Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia",
abstract = "We analysed the expression of the p53 gene in various clinical phases of chronic myelogenous leukaemia (CML) by quantitative reverse transcriptase (RT) polymerase chain reaction (PCR). Hemizygous expression of the wild-type p53 allele was observed in two samples showing the loss of one p53 allele, and affected p53 expression was associated with p53 allelic loss rather than the clinical phase of CML. In four patients with CML showing p53 inactivation, we performed a detailed sequential analysis of p53 allelic loss, p53 mutation and expression from the onset of the disease to the patients' death. Consequently, we demonstrated that the loss of a wild-type p53 allele preceded mutation of the remaining allele, and that cells hemizygous for the wild-type p53 allele dominated those with both wild-type alleles, then were replaced by cells with complete p53 inactivation. These observations indicate that not only complete p53 inactivation but also hemizggous expression of the wild-type p53 allele may confer a selective growth advantage, and that the former is implicated in a more malignant phase than the latter. Alternatively, the inactivation of another undefined anti-oncogene on chromosome 17p may allow selective growth before the p53 mutation occurs.",
keywords = "Blast crisis, Chromosome aberration, Chronic myerogenous leukaemia, Messenger RNA, p53",
author = "Hiroyuki Nakai and S. Misawa and S. Horiike and T. Maekawa and K. Kashima and K. Ishizaki",
year = "1995",
language = "English (US)",
volume = "90",
pages = "147--155",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia

AU - Nakai, Hiroyuki

AU - Misawa, S.

AU - Horiike, S.

AU - Maekawa, T.

AU - Kashima, K.

AU - Ishizaki, K.

PY - 1995

Y1 - 1995

N2 - We analysed the expression of the p53 gene in various clinical phases of chronic myelogenous leukaemia (CML) by quantitative reverse transcriptase (RT) polymerase chain reaction (PCR). Hemizygous expression of the wild-type p53 allele was observed in two samples showing the loss of one p53 allele, and affected p53 expression was associated with p53 allelic loss rather than the clinical phase of CML. In four patients with CML showing p53 inactivation, we performed a detailed sequential analysis of p53 allelic loss, p53 mutation and expression from the onset of the disease to the patients' death. Consequently, we demonstrated that the loss of a wild-type p53 allele preceded mutation of the remaining allele, and that cells hemizygous for the wild-type p53 allele dominated those with both wild-type alleles, then were replaced by cells with complete p53 inactivation. These observations indicate that not only complete p53 inactivation but also hemizggous expression of the wild-type p53 allele may confer a selective growth advantage, and that the former is implicated in a more malignant phase than the latter. Alternatively, the inactivation of another undefined anti-oncogene on chromosome 17p may allow selective growth before the p53 mutation occurs.

AB - We analysed the expression of the p53 gene in various clinical phases of chronic myelogenous leukaemia (CML) by quantitative reverse transcriptase (RT) polymerase chain reaction (PCR). Hemizygous expression of the wild-type p53 allele was observed in two samples showing the loss of one p53 allele, and affected p53 expression was associated with p53 allelic loss rather than the clinical phase of CML. In four patients with CML showing p53 inactivation, we performed a detailed sequential analysis of p53 allelic loss, p53 mutation and expression from the onset of the disease to the patients' death. Consequently, we demonstrated that the loss of a wild-type p53 allele preceded mutation of the remaining allele, and that cells hemizygous for the wild-type p53 allele dominated those with both wild-type alleles, then were replaced by cells with complete p53 inactivation. These observations indicate that not only complete p53 inactivation but also hemizggous expression of the wild-type p53 allele may confer a selective growth advantage, and that the former is implicated in a more malignant phase than the latter. Alternatively, the inactivation of another undefined anti-oncogene on chromosome 17p may allow selective growth before the p53 mutation occurs.

KW - Blast crisis

KW - Chromosome aberration

KW - Chronic myerogenous leukaemia

KW - Messenger RNA

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0029018161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029018161&partnerID=8YFLogxK

M3 - Article

C2 - 7786777

AN - SCOPUS:0029018161

VL - 90

SP - 147

EP - 155

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -